-
Product Insights
NewNet Present Value Model: Ascendis Pharma AS’s TransCon CNP
Empower your strategies with our Net Present Value Model: Ascendis Pharma AS's TransCon CNP report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Ascendis Pharma AS’s TC-TLR7/8
Empower your strategies with our Net Present Value Model: Ascendis Pharma AS's TC-TLR7/8 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – Ascendis Pharma AS
Ascendis Pharma AS (Ascendis Pharma) is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug targeting GHD (growth hormone deficiency); TransCon PTH drug to treat hypoparathyroidism by restoring physiologic levels of PTH (parathyroid hormone); and TransCon CNP, a CNP (C-type natriuretic peptide) drug against achondroplasia (ACH). It is also evaluating TransCon TLR (toll-like receptor) 7/8 agonist, and TransCon IL-2 β/γ, an interleukin-2 variant that activates...
-
Product Insights
NewNet Present Value Model: Ascendis Pharma AS’s TransCon IL-2 beta/gamma
Empower your strategies with our Net Present Value Model: Ascendis Pharma AS's TransCon IL-2 beta/gamma report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACP-017 in Vaginal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-017 in Vaginal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-017 in Vaginal Cancer Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACP-017 in Penile Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-017 in Penile Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-017 in Penile Cancer Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACP-017 in Vulvar Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-017 in Vulvar Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-017 in Vulvar Cancer Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACP-017 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-017 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-017 in Esophageal Cancer Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACP-017 in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-017 in Merkel Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-017 in Merkel Cell Carcinoma Drug Details: Small molecule is...